Clinical Trials Logo

Leukemia clinical trials

View clinical trials related to Leukemia.

Filter by:

NCT ID: NCT01138332 Completed - Leukemia Clinical Trials

Biomarkers in Young Patients With Acute Myeloid Leukemia

Start date: September 2009
Phase: N/A
Study type: Observational

RATIONALE: Studying samples of tissue from patients with cancer in the laboratory may help doctors learn more about biomarkers related to cancer. PURPOSE: This research study is studying biomarkers in tissue samples from young patients with acute myeloid leukemia.

NCT ID: NCT01138319 Completed - Leukemia Clinical Trials

Biomarkers in Patients With Acute Myeloid Leukemia

Start date: February 2009
Phase: N/A
Study type: Observational

RATIONALE: Studying samples of blood from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer. PURPOSE: This research study is studying biomarkers in patients with acute myeloid leukemia.

NCT ID: NCT01138306 Completed - Leukemia Clinical Trials

Biomarkers in Samples From Young Patients With Acute Myeloid Leukemia

Start date: February 2013
Phase: N/A
Study type: Observational

RATIONALE: Studying samples of tissue from patients with cancer in the laboratory may help doctors learn more about biomarkers related to cancer. PURPOSE: This research study is studying biomarkers in samples from young patients with acute myeloid leukemia.

NCT ID: NCT01137747 Completed - Leukemia Clinical Trials

Carfilzomib in Patients With Relapsed Acute Myeloid or Acute Lymphoblastic Leukemia

AML ALL
Start date: October 2010
Phase: Phase 1
Study type: Interventional

This study is to test escalating doses of carfilzomib in patients with relapsed acute myeloid and acute lymphoblastic leukemia.

NCT ID: NCT01135849 Completed - Breast Cancer Clinical Trials

B-Receptor Signaling in Cardiomyopathy

Start date: November 2008
Phase: N/A
Study type: Observational

We hope to determine the importance of different genes (including B receptors) in anthracycline-induced cardiomyopathy. This has important benefits to patients exposed to anthracyclines, as this could help determine whether certain individuals have increased susceptibility to cardiac injury.

NCT ID: NCT01134575 Completed - Clinical trials for Acute Lymphoblastic Leukemia

CMC-544 in Relapsed Refractory Acute Lymphoblastic Leukemia (ALL)

Start date: June 4, 2010
Phase: Phase 2
Study type: Interventional

The goal of this clinical research study is to learn if CMC-544 given alone, and possibly given in combination with rituximab, can help to control the disease in patients with ALL. The safety of the study drug(s) will also be studied.

NCT ID: NCT01133743 Completed - Clinical trials for Chronic Lymphocytic Leukemia

Open-Label Study of Lenalidomide in Combination With Oral Dexamethasone in the Treatment of Previously Untreated, Symptomatic Patients With Chronic Lymphocytic Leukemia

Start date: May 2010
Phase: Phase 2
Study type: Interventional

This is a phase II, non-randomized, single institution study in symptomatic, previously untreated CLL patients. All patients will receive the study drug, lenalidomide, given PO daily continuously on a 28 day cycle at the starting dose level of either 2.5 mgs or 5 mgs with dose escalations to a target dose of 25mg daily. Oral dexamethasone at 12 mg PO daily will be administered on days 1-7, 14 and 21 of each cycle. Patients will be treated with lenalidomide and dexamethasone to 2 cycles past CR or to a maximum of 18 cycles, each cycle of 28 days duration. Primary endpoint is response.

NCT ID: NCT01132586 Completed - Clinical trials for Recurrent Adult Acute Myeloid Leukemia

Lenalidomide, Cytarabine, and Idarubicin in Treating Patients With Acute Myeloid Leukemia

Start date: May 2010
Phase: Phase 1
Study type: Interventional

This phase I trial studies the side effects and best dose of lenalidomide when given together with cytarabine and idarubicin in treating patients with acute myeloid leukemia. Biological therapies, such as lenalidomide, may stimulate the immune system in different ways and stop cancer cells from growing. Drugs used in chemotherapy, such as cytarabine and idarubicin, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving lenalidomide together with cytarabine and idarubicin may kill more cancer cells.

NCT ID: NCT01132573 Completed - Clinical trials for Recurrent Adult Acute Lymphoblastic Leukemia

Entinostat and Clofarabine in Treating Patients With Newly Diagnosed, Relapsed, or Refractory Poor-Risk Acute Lymphoblastic Leukemia or Bilineage/Biphenotypic Leukemia

Start date: April 2010
Phase: Phase 1
Study type: Interventional

This phase I trial studies the side effects and best dose of entinostat when given together with clofarabine in treating patients with newly diagnosed, relapsed, or refractory poor-risk acute lymphoblastic leukemia or bilineage/biphenotypic leukemia. Entinostat may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as clofarabine, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving entinostat with clofarabine may kill more cancer cells.

NCT ID: NCT01130662 Completed - Clinical trials for Acute Myeloid Leukemia

Combination of Decitabine and Midostaurin in Patients Older Than 60 With Newly Diagnosed or Relapsed Refractory Acute Myeloid Leukemia

Start date: March 2010
Phase: Phase 1
Study type: Interventional

The purpose of this study is to determine the tolerated dose of the combination of decitabine and midostaurin as induction (first cycle of chemotherapy) and consolidation (additional chemotherapy once a patient goes into remission) in people greater than 60 years with newly diagnosed AML or adult patients with relapsed/refractory disease.